{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:56:10Z","timestamp":1791849370453,"version":"4.3.4"},"reference-count":64,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T00:00:00Z","timestamp":1600646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematology Reports"],"abstract":"<jats:p>The Multiple Myeloma (MM) is a plasma cells hematological malignancy with a median age of 69 years at diagnosis. The autologous stem cell transplantation is the standard of care for this disease but less than half of newly diagnosed patients are assessed for this treatment due to comorbidities or complications of disease. The management of transplant ineligible MM patients is based on the balance safety and efficacy of the new available regimen and a careful assessment of the frailty status is mandatory to define the goals. In this review we discuss of the clinical dilemmas in the management and define how to manage them based on the evidence from clinical trials and \u201creal life\u201d experience.<\/jats:p>","DOI":"10.4081\/hr.2020.8956","type":"journal-article","created":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T16:52:48Z","timestamp":1600707168000},"page":"8956","source":"Crossref","is-referenced-by-count":11,"title":["How I Manage Frontline Transplant-Ineligible Multiple Myeloma"],"prefix":"10.3390","volume":"12","author":[{"given":"Daniele","family":"Derudas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Capraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Cerchione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,9,21]]},"reference":[{"issue":"1","key":"ref1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/leu.2008.291","article-title":"Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma","volume":"23","author":"Kyle","year":"2009","journal-title":"Leukemia"},{"issue":"12","key":"ref2","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International myeloma working group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"ref3","article-title":"SEER Cancer Statistics Review. 1975 \u2013 2013. National Cancer Institute. Bethesda, MD, based on November 2015 SEER data submission, posted to the SEER web sire, April 2016","author":"Howlander","year":"2015","journal-title":"SEER Website"},{"issue":"17","key":"ref4","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1182\/blood-2011-06-358812","article-title":"Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)","volume":"118","author":"Palumbo","year":"2011","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1517\/14656566.2013.805746","article-title":"New developments in the management and treatment of newly diagnosed and relapsed\/refractory multiple myeloma patients","volume":"14","author":"van de Donk","year":"2013","journal-title":"Expert Opin Pharmacother"},{"key":"ref6"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1182\/asheducation-2013.1.488","article-title":"How should we treat newly diagnosed multiple myeloma patients?.","volume":"2013","author":"Mateos","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1634\/theoncologist.2011-0229","article-title":"Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data.","volume":"16","author":"Pulte","year":"2011","journal-title":"Oncologist"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies.","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1182\/blood-2013-07-510941","article-title":"Transplants for the elderly in myeloma","volume":"122","author":"Morgan","year":"2013","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1182\/blood-2014-09-568915","article-title":"Frontline therapy of multiple myeloma","volume":"125","author":"Moreau","year":"2015","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"iv52","DOI":"10.1093\/annonc\/mdx096","article-title":"ESMO Guidelines Committee. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Moreau","year":"2017","journal-title":"Ann Oncol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"230","DOI":"10.6004\/jnccn.2017.0023","article-title":"Multiple myeloma, version 3.2017: NCCN clinical practice guidelines in oncology","volume":"15","author":"Kumar","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/bloodadvances.2016002493","article-title":"Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States","volume":"1","author":"Costa","year":"2017","journal-title":"Blood Adv"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/bmt.2014.255","article-title":"Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years","volume":"50","author":"Auner","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"ref16","article-title":"A single autologous stem cell transplant (ASCT) followed by two years of posttransplant therapy in recently diagnosed elderly multiple myeloma (MM) patients: safety and response results from the prospective phase II Trial (NCT01849783)","author":"Nadiminti","year":"2018","journal-title":"Presented at: 60th Annual Meeting of the American Society of Hematology"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/annonc\/mdt509","article-title":"Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents","volume":"25","author":"Merz","year":"2014","journal-title":"Ann Oncol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000357394","article-title":"Japanese Society of Myeloma; European Myeloma Network. Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation: a multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network","volume":"132","author":"Ozaki","year":"2014","journal-title":"Acta Haematol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.bbmt.2017.03.012","article-title":"In-hospital mortality and post-transplantation complications in elderly multiple myeloma patients undergoing autologous hematopoietic stem cell transplantation: a population-based study","volume":"23","author":"Sanchez","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1182\/blood-2013-02-483073","article-title":"Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results","volume":"122","author":"Gay","year":"2013","journal-title":"Blood"},{"key":"ref21","article-title":"One-year update of a phase 3 randomized study of daratumumab plus bortezomib, melphalan, and prednisone (D-VMP) versus bortezomib, melphalan, and prednisone (VMP) in patients (pts) with transplant-ineligible newly diagnosed multiple myeloma (NDMM): ALCYONE. Presented at: 60th Annual Meeting of the American Society of Hematology","author":"Dimopoulos","year":"2018"},{"key":"ref22","article-title":"Phase 3 randomized study of daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) in patients with newly diagnosed multiple myeloma (NDMM) ineligible for transplant (MAIA)","author":"Facon","year":"2018","journal-title":"Presented at: 60th Annual Meeting of the American Society of Hematology"},{"key":"ref23","article-title":"One-year update of a phase 3 randomized study of daratumumab plus bortezomib, melphalan, and prednisone (D-VMP) versus bortezomib, melphalan, and prednisone (VMP) in patients (pts) with transplant-ineligible newly diagnosed multiple myeloma (NDMM): ALCYONE. Presented at: 60th Annual Meeting of the American Society of Hematology","author":"Dimopoulos","year":"2018"},{"issue":"3","key":"ref24","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/bjc.2014.307","article-title":"The association of diabetes and antidiabetic medications with clinical outcomes in multiple myeloma","volume":"111","author":"Wu","year":"2014","journal-title":"Br J Cancer"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"980","DOI":"10.3324\/haematol.2012.075051","article-title":"Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials","volume":"98","author":"Bringhen","year":"2013","journal-title":"Haematologica"},{"issue":"13","key":"ref26","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patient: an International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"key":"ref27","first-page":"3152","article-title":"Vulnerability variables among octagenarians myeloma patients: a single- center analysis in 110 patients","author":"Gavriatopoulou","year":"2017","journal-title":"ASH 2017, Blood"},{"issue":"5","key":"ref28","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3324\/haematol.2016.162693","article-title":"A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients","volume":"102","author":"Engelhardt","year":"2017","journal-title":"Haematologica"},{"issue":"3","key":"ref29","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jgo.2018.10.010","article-title":"Performance of the International Myeloma Working Group myeloma frailty score among 75 and older","volume":"10","author":"Murillo","year":"2019","journal-title":"J Geriatr.Oncol"},{"issue":"11","key":"ref30","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1182\/blood-2010-09-307645","article-title":"Complete response correlates with long-term progression-free survival in elderly myeloma treated with novel agents: analysis of 1175 patients","volume":"117","author":"Gay","year":"2011","journal-title":"Blood"},{"issue":"9594","key":"ref31","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","article-title":"Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomized trial","volume":"370","author":"Facon","year":"2007","journal-title":"Lancet"},{"issue":"9","key":"ref32","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1182\/blood-2009-08-237974","article-title":"Melphalan and prednisone plus thalidomide or plascebo in elderly patients with multiple myeloma","volume":"116","author":"Waage","year":"2010","journal-title":"Blood"},{"issue":"19","key":"ref33","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1200\/JCO.2009.26.1610","article-title":"Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 study","volume":"28","author":"Wijermans","year":"2010","journal-title":"J Clin Oncol"},{"issue":"22","key":"ref34","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1200\/JCO.2008.21.0948","article-title":"Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01\/01 trial","volume":"27","author":"Hulin","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"ref35","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1600-0609.2010.01524.x","article-title":"Addition of thalidomide to oral melphalan\/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group","volume":"86","author":"Beksac","year":"2011","journal-title":"Eur J Haematol"},{"issue":"10","key":"ref36","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.3109\/10428194.2011.584006","article-title":"A randomized trial with melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant","volume":"52","author":"Sacchi","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus Melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San","year":"2008","journal-title":"N Engl J Med"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2009.26.0638","article-title":"Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and im- pact of subsequent therapy in the phase III VISTA trial","volume":"28","author":"Mateos","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1182\/blood-2010-07-294983","article-title":"Efficacy and safety of once-weekly bortezomib in multiple myeloma patients","volume":"116","author":"Bringhen","year":"2010","journal-title":"Blood"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1200\/JCO.2010.29.8216","article-title":"Bortezomib- melphalan-prednisonethalidomide followed by maintenance with bortezomib- thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial","volume":"28","author":"Palumbo","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1200\/JCO.2013.52.0023","article-title":"Bortezomib-melphalan-prednisone- thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalanprednisone for in- itial treatment of multiple myeloma: updated follow-up and improved survival","volume":"32","author":"Palumbo","year":"2014","journal-title":"J Clin Oncol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S1470-2045(10)70187-X","article-title":"Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and pre- dnisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with un- treated multiple myelom","volume":"11","author":"Mateos","year":"2010","journal-title":"Lancet Oncol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1182\/blood-2014-05-573733","article-title":"GEM2005 trial update comparing VMP\/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?","volume":"124","author":"Mateos","year":"2014","journal-title":"Blood"},{"issue":"11","key":"ref45","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1182\/blood-2014-12-613927","article-title":"Melphalan, prednisone and thalidomide versus melphalan, prednisone and lenalidomide (ECOG E1A06) in untreated multiple myeloma","volume":"126","author":"Stewart","year":"2015","journal-title":"Blood"},{"issue":"19","key":"ref46","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous lenalidomidetratment for newly diagnosed multiple myeloma","volume":"366","author":"Palumbo","year":"2012","journal-title":"N Engl J med"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"N Engl J Med"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"826","DOI":"10.3324\/haematol.2014.120121","article-title":"Health- related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide","volume":"100","author":"Delforge","year":"2015","journal-title":"Haematologica"},{"key":"ref49","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stemcell transplant (SWOG S0777): a randomized, open-label, phase 3 trial. Lancet. 2016. Large phase III trial establishing bortezomib-lenalidomidedexamethasone (VRd) therapy as the current standard of care for transplant ineligible MM in the US","author":"Durie"},{"issue":"21","key":"ref50","doi-asserted-by":"crossref","first-page":"3454","DOI":"10.1182\/blood.V124.21.3454.3454","article-title":"A phase II study of modified lenalidomide, bortezomib, and dexamethasone (RVD lite) for transplantineligicle patents with newly diagnosed multiple myeloma","volume":"124","author":"O\u2019Donnell","year":"2014","journal-title":"Blood"},{"issue":"6","key":"ref51","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N Engl J med"},{"issue":"22","key":"ref52","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"ref53","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma: 2020 update on diagnosis, risk-stratification and management","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am J Hematol"},{"issue":"10","key":"ref54","first-page":"1154","article-title":"NCCN Guidelines Insights: Multiple Myeloma, version1.2020","volume":"17","author":"Kumar","journal-title":"J Natl Compr Can Netw 2019 Oct 1"},{"issue":"19","key":"ref55","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1182\/blood-2015-05-612960","article-title":"I how treat fragile myeloma patients","volume":"126","author":"Larocca","year":"2015","journal-title":"Blood"},{"issue":"13","key":"ref56","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(14)71125-8","article-title":"Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1\/2study","volume":"15","author":"Kumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"17","key":"ref57","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N Eng J Med"},{"issue":"10","key":"ref58","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/17474086.2018.1518129","article-title":"Ixazomib: a novel drug for multiple myeloma","volume":"11","author":"Zanwar","year":"2018","journal-title":"Exert Rev Hematol"},{"issue":"7","key":"ref59","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lional","year":"2015","journal-title":"N Eng J med"},{"issue":"19","key":"ref60","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","article-title":"Elotuzumab plus pomalidomide and dexamethasone for multliple myeloma","volume":"379","author":"Domopoulos","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"ref61","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomized, phase 3, open-label, multicenter study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol"},{"issue":"3","key":"ref62","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/bjh.14549","article-title":"Carfilzomib, lenalidomide e dexamethasone in patients with relapsed multiple myeloma categorized by age: secondary analysis from the phase 3 ASPIRE study","volume":"177","author":"Dimopoulos","year":"2017","journal-title":"Br J Haematol"},{"issue":"14","key":"ref63","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, Lenalidomide and Dexamethasone for Multiple Myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"ref64","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, Bortezomib and Dexamethasone for Multiple Myeloma.","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med"}],"container-title":["Hematology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.pagepress.org\/journals\/index.php\/hr\/article\/download\/8956\/8416","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.mdpi.com\/2038-8330\/12\/11\/8956\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T07:34:06Z","timestamp":1645601646000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2038-8330\/12\/11\/8956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,21]]},"references-count":64,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,9]]}},"alternative-id":["hr.2020.8956"],"URL":"https:\/\/doi.org\/10.4081\/hr.2020.8956","relation":{},"ISSN":["2038-8330"],"issn-type":[{"value":"2038-8330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,21]]}}}